{
    "nct_id": "NCT04810598",
    "official_title": "Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function",
    "inclusion_criteria": "* Body mass index (BMI) between 18.0 and 42.0 kg/m2.\n* Postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Women of childbearing potential, practicing at least 2 protocol specified methods of birth control that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug.\n* Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG) with normal Glomerular Filtration Rate (GFR) at Screening.\n* Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "- Participants on a strict vegetarian or vegan diet.",
    "miscellaneous_criteria": ""
}